Market Research

Psychedelic Invest is your source for the latest business and investing news about the burgeoning psychedelics industry.

Blog

Tripping Around The World: The Global Legal Landscape of Psychedelics

Psychedelics have been illegal in much of the world for over half a century. However, that is starting to change. As the medical and spiritual benefits of psychedelics become increasingly apparent, more cities, states, and countries are changing the laws that govern these compounds. The following is an outline of the global laws governing psychedelics as of June 1, 2023. Fortunately, laws are constantly changing! To stay up to date on where psychedelics are legalized and decriminalized, keep an eye on our legal guide, which is constantly being updated to reflect changes in regulations. Legalized VS Decriminalized Many cities, states,…

Blog

Psychedelic Search Trends: Insights into the Rising Popularity and Geographic Preferences of Mind-Altering Experiences

In today’s data-driven world, understanding search trends can provide invaluable insights into the evolving interests and preferences of the public. By harnessing the power of Google Trends, which offers data from trillions of searches worldwide, we can witness the trends and patterns within the psychedelic industry. This analysis will decipher the search trend data and shed light on the surges in interest surrounding psychedelic topics in the United States. Google Trends offers data obtained through the search engine, which has trillions of searches executed around the world every year. It is a valuable tool to assess the popularity of different…

Blog

BREAKING: Kentucky To Invest in Ibogaine Treatment for Addiction

Earlier today during a press conference, the Opioid Abatement Advisory Commission held a press conference announcing its intended focus on treatments for addiction, most specifically ibogaine treatments for opioid addiction. Approximately $42 million will be allocated over the next seven years to develop safety protocols and to host clinical trials for ibogaine. “Ibogaine is an alkaloid derived from three plant sources” found in West African countries. “Anecdotal evidence that is a mountain high and decades wide suggests that ibogaine, within 48 to 72 hours of administration in safe, clinically-controlled conditions, resolves opioid withdrawal syndrome,” exclaimed W. Bryan Hubbard, who chairs…

Blog

Unleashing the Full Potential of Psychedelic Therapy

Bridging the Gender Gap for Enhanced Healthcare Solutions The psychedelic industry is gaining momentum and attracting passionate individuals who see the potential for profound healing and transformation. However, there is a glaring disparity within this burgeoning industry: it is primarily being led and shaped by men. With 91% of leadership roles held by men, there is a significant underrepresentation of women in the decision-making process.  This gender imbalance becomes concerning when we consider that many of the conditions targeted by psychedelic therapies disproportionately affect women. Mental illnesses, such as depression, are more prevalent among women, and they are also more…

Blog

Is the American Medical Association Ready for Psychedelics?

Though psychedelics are gaining mainstream support from media and patients alike, the medical institution is not as quick to voice its unwavering support. Bureaucracy moves much slower than the rest of the world, but even that has begun to move in a positive direction for psychedelic medicine. On May 2, it was announced that the American Medical Association is crafting a set of CPT codes for psychedelic-assisted therapy, which will help increase access once MDMA and psilocybin become FDA-approved. The application was a joint effort by Compass Pathways and MAPS, and it will support both companies’ ability to commercialize their…